0.08
-0.0056(-6.94%)
Currency In USD
| Previous Close | 0.08 |
| Open | 0.08 |
| Day High | 0.08 |
| Day Low | 0.07 |
| 52-Week High | 173 |
| 52-Week Low | 0.06 |
| Volume | 70,800 |
| Average Volume | 10.43M |
| Market Cap | 2.2M |
| PE | 0 |
| EPS | 62.6 |
| Moving Average 50 Days | 0.47 |
| Moving Average 200 Days | 4.49 |
| Change | -0.01 |
If you invested $1000 in Windtree Therapeutics, Inc. (WINT) 10 years ago, it would be worth $0 as of September 18, 2025 at a share price of $0.075. Whereas If you bought $1000 worth of Windtree Therapeutics, Inc. (WINT) shares 5 years ago, it would be worth $0 as of September 18, 2025 at a share price of $0.075.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting
GlobeNewswire Inc.
Sep 02, 2025 1:00 PM GMT
The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders The stockholder approved proposals provide the foundation for Windtree revenue generating deals in environment
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
GlobeNewswire Inc.
Aug 11, 2025 1:00 PM GMT
Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30% Istaroxime interim data was consistent with the profil
Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients
GlobeNewswire Inc.
Aug 05, 2025 1:00 PM GMT
Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous trials Cardiogenic shock is a severe pres